NeoGenomics Schedules its Q4 and Full Year 2012 Earnings Release for February
FT. MYERS, Fla., Feb. 5, 2013
FT. MYERS, Fla., Feb. 5, 2013 /PRNewswire/ --NeoGenomics, Inc. (NASDAQ: NEO)
announced today that it plans to release its fourth quarter and full year 2012
financial results on Thursday February 14, 2013.
The Company has scheduled a web-cast and conference call to discuss their Q4
and full year 2012 results on February 14, 2013 at 11:00 AM EST. Interested
investors should dial (800) 374-1317 (domestic) and (404) 665-9940
(international) at least five minutes prior to the call and ask for Conference
ID 97486925. An archive of the conference call will be available at
https://us.reg.meeting-stream.com/neogenomicsinc_021413/ for a period of one
year from the date of the conference call. The web-cast may be accessed under
the Investor Relations section of our website at http://www.neogenomics.comor
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that
specializes in cancer genetics diagnostic testing, the fastest growing segment
of the laboratory industry. The company's testing services include
cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry,
immunohistochemistry, anatomic pathology and molecular genetic testing.
Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN,
Irvine, CA, Tampa and Fort Myers, FL. NeoGenomics services the needs of
pathologists, oncologists, other clinicians and hospitals throughout the
United States. For additional information about NeoGenomics, visit
Interested parties can also access investor relations material from Hawk
Associates at http://www.hawkassociates.com or firstname.lastname@example.org and from
Zack's Investment Research at http://www.zacks.com or email@example.com.
Forward Looking Statements
Except for historical information, all of the statements, expectations and
assumptions contained in the foregoing are forward-looking statements. These
forward looking statements involve a number of risks and uncertainties that
could cause actual future results to differ materially from those anticipated
in the forward looking statements, Actual results could differ materially from
such statements expressed or implied herein. Factors that might cause such a
difference include, among others, the company's ability to continue gaining
new customers, offer new types of tests, and otherwise implement its business
plan. As a result, this press release should be read in conjunction with the
company's periodic filings with the SEC.
SOURCE NeoGenomics, Inc.
Contact: Steven C. Jones, Director of Investor Relations, NeoGenomics, Inc.,
+1-239-325-2001, firstname.lastname@example.org; or Ms. Julie Marshall, Hawk
Associates, Inc., +1-305-451-1888, email@example.com
Press spacebar to pause and continue. Press esc to stop.